Peer Exchange


Reducing Disease Burden Through Early Diagnosis and Treatment of Spinal Muscular Atrophy (SMA)

April 20th 2021

Dennis P. Scanlon, PhD; Emma Ciafaloni, MD; Maria Lopes, MD, MS; Kevin U. Stephens, Sr, JD, MD; and Mary Schroth, MD, FAAP, FCCP provide an overview of the disease burden in spinal muscular atrophy and give insight into clinical and payor perspectives on screening and diagnosis, current treatment options, and new disease-modifying therapies in SMA.

Reducing Alzheimer’s Disease Burden Through Early Diagnosis and Treatment

March 10th 2021

A panel of experts highlight the burden of Alzheimer’s disease and current unmet needs related to diagnosis and treatment, discuss clinical and payer considerations for the diagnosis and management of AD, and generate discussion around future directions in the diagnosis and treatment.

Exploring the Implementation of Quality Care Programs for Patients with Myeloproliferative Neoplasms

February 24th 2021

Bruce Feinberg, DO; Kathy Oubre, Michael Reff, RPh, MBA; Jamile M. Shammo, MD; and Ruben Mesa, MD, discuss the incorporation of quality care programs for improved disease management and patient care for MPNs.

Emerging Treatment Options in Relapsed Refractory Multiple Myeloma

January 27th 2021

A panel of experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide practical considerations for regimen selection and emerging treatment options.

Acute and Preventive Therapy for Migraine

January 20th 2021

Key opinion leaders discuss the differences between acute and preventive treatment in migraine, clinical guidelines and treatment selections, and options for migraine management and prevention.

Implications of Expanding Use of CAR T-Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

December 11th 2020

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.

Supporting Cross-Benefit Management of Infused Drugs

October 12th 2020

Optimizing the clinical and financial aspects of disease management when covering an infused drug product under the pharmacy and medical benefit.

Considering Cost Effectiveness in Cardiovascular Risk Reduction

September 16th 2020

Quantifying the Potential Impact of SGLT-2 Inhibitors in Heart Failure

September 11th 2020

Value-based Considerations of CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer

September 2nd 2020